The Technical Analyst
AVROBIO Inc [AVRO]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
AVROBIO Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.42% $1.185
America/New_York / 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 53.16 mill |
| EPS: | 0.270 |
| P/E: | 4.39 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 44.86 mill |
| Avg Daily Volume: | 0.298 mill |
| RATING 2024-04-25 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 4.39 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.75x |
| Company: PE 4.39 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$2.19 (84.47%) $1.001 |
| Date: 2024-04-25 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.131 - 1.249 ( +/- 4.96%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-01 | Golipour Azadeh | Sell | 37 334 | Restricted Stock Unit |
| 2024-02-01 | Golipour Azadeh | Buy | 37 334 | Common Stock |
| 2024-02-05 | Golipour Azadeh | Sell | 12 232 | Common Stock |
| 2024-02-01 | Ridha Essra | Sell | 32 834 | Restricted Stock Unit |
| 2024-02-01 | Ridha Essra | Buy | 32 834 | Common Stock |
| INSIDER POWER |
|---|
| 54.79 |
| Last 100 transactions |
| Buy: 6 327 240 | Sell: 1 294 974 |
Forecast:
16:00 - $1.190
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.190
Forecast 2: 16:00 - $1.190
Forecast 3: 16:00 - $1.190
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.185 (-0.42% ) |
| Volume | 0.0947 mill |
| Avg. Vol. | 0.298 mill |
| % of Avg. Vol | 31.83 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AVRO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
AVRO
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Last 10 Buy Signals
Latest Press Releases
2024-02-14 11:11:00 - Press Release
Avrobio Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Merger Of Avrobio, Inc. - Avro
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed merger of avrobio, inc. (nasdaqgs: avro) and tectonic therapeutic, inc. pursuant to which pre-merger avrobio shareholders are expected to own approximately 22.3% of the combined company. ksf is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the co.
2024-01-31 15:08:00 - Press Release
Shareholder Alert: Ademi Llp Investigates Whether Avrobio, Inc. Has Obtained A Fair Price In Its Transaction With Tectonic
Milwaukee , jan. 31, 2024 /prnewswire/ -- ademi llp is investigating avrobio, inc. (nasdaq: avro) for possible breaches of fiduciary duty and other violations of law in its transaction with tectonic. click here to learn how to join the https://www.ademilaw.com/case/avrobio-inc or call guri ademi toll-free at 866-264-3995.
2024-01-30 09:04:00 - Press Release
Avro Stock Alert: Halper Sadeh Llc Is Investigating Whether The Merger Of Avrobio, Inc. Is Fair To Shareholders
New york--(business wire)--halper sadeh llc, an investor rights law firm, is investigating whether the merger of avrobio, inc. (nasdaq: avro) and tectonic therapeutic, inc. is fair to avrobio shareholders. upon completion of the proposed transaction, pre-merger avrobio shareholders are expected to own approximately 22.3% of the combined company. halper sadeh encourages avrobio shareholders to click here to learn more about their legal rights and options or contact daniel sadeh or zachary halper.
2024-01-30 08:00:00 - Press Release
Avrobio And Tectonic Therapeutic Announce Merger
Cambridge, mass. & watertown, mass.--(business wire)---- $avro--avrobio, inc. (nasdaq: avro) and tectonic therapeutic, inc. (“tectonic”), a privately-held biotechnology company developing gpcr (g-protein coupled receptor)-targeted therapeutic proteins, co-founded by timothy a. springer and andrew c. kruse of harvard medical school, today announced that the companies have entered into a definitive merger agreement to combine in an all-stock transaction (the “merger”). under the terms of the agreement, avr.
2023-07-12 07:00:00 - Press Release
Avrobio To Explore Strategic Alternatives
Cambridge, mass.--(business wire)---- $avro--avrobio, inc. (nasdaq: avro), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities. avrobio has made the determination to halt further development of its programs and to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value. as part o.
Latest News
2023-11-08 11:17:36 - Zacks Investment Research
Is AVROBIO (AVRO) Stock Outpacing Its Medical Peers This Year?
Here is how AVROBIO, Inc. (AVRO) and Crinetics Pharmaceuticals, Inc. (CRNX) have performed compared to their sector so far this year.
2023-10-23 11:17:51 - Zacks Investment Research
Is AVROBIO (AVRO) Outperforming Other Medical Stocks This Year?
Here is how AVROBIO, Inc. (AVRO) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.
2023-10-06 11:17:22 - Zacks Investment Research
Has AVROBIO (AVRO) Outpaced Other Medical Stocks This Year?
Here is how AVROBIO, Inc. (AVRO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
2023-08-12 04:03:14 - Seeking Alpha
Avrobio: Net-Net Biotech Pursuing Strategic Alternatives
After monetizing one of its pipeline candidates, Avrobio has cash well in excess of its market cap. The company announced its search for strategic alternatives recently. The process could close its valuation gap soon. There is potential for significantly more value if Avrobio can also monetize its remaining candidates.
2023-07-13 08:51:14 - Zacks Investment Research
AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46%
AVROBIO (AVRO) announces its decision to halt all development programs in its quest to explore strategic alternatives. The stock of the company surges 46% in response on Wednesday.
2023-05-23 06:00:00 - PennyStocks
How to Handle Penny Stocks Volatility in 2023
Penny stocks continue to offer incredible opportunities for investors in 2023. As high-growth, micro-cap equities, they have the potential to outperform traditional stocks, particularly given their inherent affordability, which allows for a broader, more diversified portfolio.
2023-05-22 11:43:35 - InvestorPlace
Why Is AVROBIO (AVRO) Stock Up 83% Today?
AVROBIO (NASDAQ: AVRO ) stock is seeing massive gains on Monday as the company sells one of its gene therapies to Novartis (NYSE: NVS ). This deal has Novartis agreeing to pay $87.5 million in cash to AVROBIO for an investigational hematopoietic stem cell ( HSC ) gene therapy program.
2022-05-18 16:33:03 - Zacks Investment Research
AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study
Results from AVROBIO's (AVRO) phase I/II study, which is evaluating its gene-therapy candidate for cystinosis, show the latter's potential to stabilize or reduce the impact of cystinosis on different tissues.
2022-05-17 12:21:03 - Benzinga
AVROBIO Shares Jumps On Encouraging Data From Early-Stage Gene Therapy Study
AVROBIO Inc (NASDAQ: AVRO) reported new interim data from the Phase 1/2 gene therapy trial of AVR-RD-04 for cystinosis. Cystinosis is a condition characterized by the accumulation of the amino acid cystine (a building block of proteins) within cells.
2022-02-09 12:55:35 - Benzinga
After Fabry Trial Setback, Avrobio Hopes Rebound With Lysosomal Storage Disorder Data
Avrobio Inc's AVRO gene therapy for a rare lysosomal storage disorder showed potential durability in the first three patients more than one year after infusion. Get the Inside Access Traders Are Using to Profit More and Win Bigger.